Pembrolizumab as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma
Posted: 04/17/2024 | By: Chase Doyle

The KEYNOTE-716 study evaluated the safety and efficacy of pembrolizumab compared to placebo in resected high-risk stage II melanoma. A recent analysis from the trial was published by Luke et al in the Journal of Clinical Oncology.

Question 1 of 5

What was the primary endpoint of the KEYNOTE-716 study?

Choose 1